Page last updated: 2024-08-24

gemcitabine and oblongifolin c

gemcitabine has been researched along with oblongifolin c in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cai, S; Chen, X; Lao, Y; Li, Y; Liang, C; Tan, H; Wang, Z; Xi, Z; Xu, H	1

Other Studies

1 other study(ies) available for gemcitabine and oblongifolin c

Article	Year
Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Cell death & disease, 2018, 05-01, Volume: 9, Issue:5 Topics: Animals; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Terpenes; Xenograft Model Antitumor Assays	2018

Article

Year

Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways.

Cell death & disease, 2018, 05-01, Volume: 9, Issue:5

Topics: Animals; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Terpenes; Xenograft Model Antitumor Assays

2018